FDA rejection and value
22:43–23:50 · 67s
After meeting endpoints, Cindy recounts the FDA’s 'no' and challenges the idea that women’s sexual health benefits are too 'modest' to merit any risk.
22:43–23:50 · 67s
After meeting endpoints, Cindy recounts the FDA’s 'no' and challenges the idea that women’s sexual health benefits are too 'modest' to merit any risk.
We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.